Editorial comment: An intact and functional vascular system that supplies the penis is well recognized to be necessary for the hemodynamic mechanisms of erection physiology. This fundamental insight makes a strong case for the study and application of factors that control vascular formation and perfusion in the erectile tissues of the penis. These investigators have identi®ed vascular endothelial growth factor (VEGF) as a likely signi®cant angiogenic agent in the penis and sought to characterize its expression. They carried out reverse transcription-polymerase chain reaction techniques (RT-PCR) and RNase protection assays to analyze and quantify VEGF mRNA transcripts representing splice variants in rat and human penile tissues. Among four previously described splice variants of VEGF mRNA (VEGF 120, 144, 164, and 188), VEGF 164 was found to be the most abundant transcript detected in the penis. A novel VEGF splice variant corresponding to a possible protein of 110 amino acid residues (VEGF 110) was also detected in the rat penis. This mainly descriptive study offers opportunities to devise therapies related to manipulation of VEGF expression in the penis in order to treat vasculogenic erectile dysfunction. Perhaps, a regionally speci®c therapy can be developed based on the characterizations provided by this study.
Further work in this area should be undertaken immediately to test the biological activities of these proposed protein-encoding target transcripts in the penis.
